Next Article in Journal
The Profile of MicroRNA Expression in Bone Marrow in Non-Hodgkin’s Lymphomas
Previous Article in Journal
Multimodal Imaging and Biomarkers in Cardiac Amyloidosis
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Novel Usefulness of Krebs von den Lungen 6 (KL-6) with Hemoglobin and Lactate Dehydrogenase for Assessing Bone Marrow Fibrosis

1
Department of Laboratory Medicine, Korea University Anam Hospital, Seoul 02841, Korea
2
Department of Laboratory Medicine, Konkuk University School of Medicine, Seoul 05030, Korea
3
Department of Laboratory Medicine, Eunpyeong St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea
*
Author to whom correspondence should be addressed.
Diagnostics 2022, 12(3), 628; https://doi.org/10.3390/diagnostics12030628
Submission received: 23 December 2021 / Revised: 24 February 2022 / Accepted: 1 March 2022 / Published: 3 March 2022
(This article belongs to the Section Pathology and Molecular Diagnostics)

Abstract

Bone marrow fibrosis (BMF) is manually assessed by reticulin and trichrome stain of bone marrow (BM) biopsy and graded on a semi-quantitative scale. Krebs von den Lungen 6 (KL-6) and Mac-2 binding protein glycosylation isomer (M2BPGi) are known to be associated with lung and liver fibrosis, respectively. We explored the usefulness of KL-6 and M2BPGi to assess BMF. A total of 250 patients who underwent BM biopsy with hematologic or non-hematologic diseases were included, and 42 patients with lung and liver diseases were excluded. The patients’ data, including age, sex, diagnosis, white blood cell, hemoglobin (Hb), platelet, and lactate dehydrogenase (LDH) were collected. Measured KL-6 and M2BPGi levels were compared with reticulin grade (RG) (grade 0–3). KL-6 levels were significantly elevated with an increase in RG, but M2BPGi did not show a significant difference. Hb, LDH, or KL-6 were independent predictors for BMF (odds ratio: 1.96, 2.26, 2.91, respectively), but showed poor predictive ability (area under the curve [AUC] 0.62, 0.61, 0.60, respectively). The combination of Hb, LDH, and KL-6 showed a significantly improved predictive ability for BMF (AUC 0.73; integrated discrimination improvement 0.057; category-free net reclassification improvement 0.625). This is the first study to evaluate the usefulness of KL-6 for assessing BMF. The combination of Hb, LDH, and KL-6 would be an objective and relevant biomarker approach and be applied to risk stratification for BMF.
Keywords: bone marrow fibrosis; KL-6; M2BPGi; Hb; LDH bone marrow fibrosis; KL-6; M2BPGi; Hb; LDH

Share and Cite

MDPI and ACS Style

Nam, M.; Hur, M.; Park, M.; Kim, H. Novel Usefulness of Krebs von den Lungen 6 (KL-6) with Hemoglobin and Lactate Dehydrogenase for Assessing Bone Marrow Fibrosis. Diagnostics 2022, 12, 628. https://doi.org/10.3390/diagnostics12030628

AMA Style

Nam M, Hur M, Park M, Kim H. Novel Usefulness of Krebs von den Lungen 6 (KL-6) with Hemoglobin and Lactate Dehydrogenase for Assessing Bone Marrow Fibrosis. Diagnostics. 2022; 12(3):628. https://doi.org/10.3390/diagnostics12030628

Chicago/Turabian Style

Nam, Minjeong, Mina Hur, Mikyoung Park, and Hanah Kim. 2022. "Novel Usefulness of Krebs von den Lungen 6 (KL-6) with Hemoglobin and Lactate Dehydrogenase for Assessing Bone Marrow Fibrosis" Diagnostics 12, no. 3: 628. https://doi.org/10.3390/diagnostics12030628

APA Style

Nam, M., Hur, M., Park, M., & Kim, H. (2022). Novel Usefulness of Krebs von den Lungen 6 (KL-6) with Hemoglobin and Lactate Dehydrogenase for Assessing Bone Marrow Fibrosis. Diagnostics, 12(3), 628. https://doi.org/10.3390/diagnostics12030628

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop